+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis

Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis

Shock 8(5): 349-356

The overzealous production of proinflammatory cytokines in sepsis can result in shock, multiorgan dysfunction, and even death. In this study we assessed the role of endogenously produced interleukin (IL)-12 in murine models of endotoxemia and Gram-negative peritoneal sepsis. Initial studies indicated that intraperitoneal lipopolysaccharide (LPS) administration to mice induced a significant time-dependent increase in plasma, lung, and liver IL-12 levels. Passive immunization with anti-IL-12 serum intraperitoneally before LPS resulted in a marked reduction in plasma levels of tumor necrosis factor and interferon-gamma. Furthermore, we observed an increase in endotoxin-induced mortality in mice transiently overexpressing murine IL-12 using a recombinant adenoviral vector (Ad5 mIL-12) administered intraperitoneally. Neutralization of tumor necrosis factor or interferon-gamma in animals overexpressing IL-12 resulted in significant reductions in LPS-induced mortality, suggesting that the mechanism whereby IL-12 increases LPS-induced mortality is primarily mediated by the enhancement of these cytokines. In contrast, we observed no survival benefit in animals passively immunized with anti-IL-12 serum before the intraperitoneal administration of 2 x 10(8) live Escherichia coli. Interestingly, there was an approximately 70-fold increase in peritoneal fluid E. coli colony-forming units and the early onset of bacteremia in animals treated with anti-IL-12 serum, as compared with control animals. These results indicate that IL-12 is produced in response to LPS exposure, and the neutralization of this cytokine improves survival in endotoxin-challenged animals. However, IL-12 represents an essential component of antibacterial host defense, as anti-IL-12 therapy results in significant impairment in the host's ability to clear Gram-negative bacterial infection.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 045269878

Download citation: RISBibTeXText

PMID: 9361345

DOI: 10.1097/00024382-199711000-00006

Related references

Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. Journal of Immunology 164(5): 2644-2649, 2000

Escherichia coli lipopolisacharide (LPS) induced endotoxemia in horses: effects of anti-inflammatory drugs on seric and peritoneal tumor necrosis factor alpha (TNF-alpha) concentrations FT Endotoxemia por lipopolissacarideo de Escherichia coli, em equinos: efeitos de antiinflamatorios nas concentracoes serica e peritoneal do fator de necrose tumoral alfa (TNF-alpha). 2007

Hepcidin Protects against Lethal Escherichia coli Sepsis in Mice Inoculated with Isolates from Septic Patients. Infection and Immunity 86(7), 2018

Interleukin 10 protects mice from lethal endotoxemia. Journal of Experimental Medicine 177(4): 1205-1208, 1993

Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection. Journal of Experimental Medicine 169(6): 2021-2027, 1989

The Methanol Extract of Azadirachta indica A. Juss Leaf Protects Mice Against Lethal Endotoxemia and Sepsis. Biomolecules and Therapeutics 20(1): 96-103, 2012

Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge. Infection and Immunity 73(8): 4810-4817, 2005

The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. Journal of Nutrition 136(2): 360-365, 2006

Monoclonal antibody to endotoxin core protects mice from Escherichia coli sepsis by a mechanism independent of tumor necrosis factor and interleukin-6. Journal of Infectious Diseases 162(2): 454-459, 1990

The role of anti-tumor necrosis factor-alpha and interleukin-10 in protecting murine neonates from Escherichia coli sepsis. Journal of Pediatric Surgery 35(6): 852-4; Discussion 855, 2000

Combination therapy of 15-epi-lipoxin A4 with antibiotics protects mice from Escherichia coli-induced sepsis*. Critical Care Medicine 42(4): E288-E295, 2014

TLR4 inhibition impairs bacterial clearance in a therapeutic setting in murine abdominal sepsis. Inflammation Research 63(11): 927-933, 2015

Interleukin -10 deficient mice suffer from enhanced multiple organ dysfunction during Escherichia coli peritonitis in spite of a more efficient bacterial clearance. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 64, 2000

The influence of anti-inflammatory therapy on bacterial clearance following intramammary Escherichia coli challenge in goats. Veterinary Research Communications 15(2): 147-161, 1991

Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge. Microbial Biotechnology 5(2): 283-294, 2013